Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer

Tanja N Fehm; Manfred Welslau; Volkmar Müller; Diana Lüftner; Florian Schütz; Peter A Fasching; Wolfgang Janni; Christoph Thomssen; Isabell Witzel; Erik Belleville; Michael Untch; Marc Thill; Hans Tesch; Nina Ditsch; Michael P Lux; Bahriye Aktas; Maggie Banys-Paluchowski; Andreas Schneeweiss; Cornelia Kolberg-Liedtke; Andreas D Hartkopf; Achim Wöckel; Hans-Christian Kolberg; Nadia Harbeck; Elmar Stickeler

doi:10.1055/a-1912-7105

Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer

Tanja N Fehm, Manfred Welslau, Volkmar Müller, Diana Lüftner, Florian Schütz, Peter A Fasching, Wolfgang Janni, Christoph Thomssen, Isabell Witzel, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P Lux, Bahriye Aktas, Maggie Banys-Paluchowski, Andreas Schneeweiss, Cornelia Kolberg-Liedtke, Andreas D HartkopfAchim Wöckel, Hans-Christian Kolberg, Nadia Harbeck, Elmar Stickeler

1 Citation (Scopus)

Abstract

This review summarizes recent developments in the prevention and treatment of patients with early-stage breast cancer. The individual disease risk for different molecular subtypes was investigated in a large epidemiological study. With regard to treatment, new data are available from long-term follow-up of the Aphinity study, as well as new data on neoadjuvant therapy with atezolizumab in HER2-positive patients. Biomarkers, such as residual cancer burden, were investigated in the context of pembrolizumab therapy. A Genomic Grade Index study in elderly patients is one of a group of studies investigating the use of modern multigene tests to identify patients with an excellent prognosis in whom chemotherapy may be avoided. These and other aspects of the latest developments in the diagnosis and treatment of breast cancer are described in this review.

Original language	English
Journal	Geburtshilfe und Frauenheilkunde
Volume	82
Issue number	9
Pages (from-to)	912-921
Number of pages	10
ISSN	0016-5751
DOIs	https://doi.org/10.1055/a-1912-7105
Publication status	Published - 09.2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Centers: University Cancer Center Schleswig-Holstein (UCCSH)
Research Area: Luebeck Integrated Oncology Network (LION)

DFG Research Classification Scheme

2.22-14 Hematology, Oncology
2.22-21 Gynaecology and Obstetrics

Access to Document

10.1055/a-1912-7105

Cite this

Fehm, T. N., Welslau, M., Müller, V., Lüftner, D., Schütz, F., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., Belleville, E., Untch, M., Thill, M., Tesch, H., Ditsch, N., Lux, M. P., Aktas, B., Banys-Paluchowski, M., Schneeweiss, A., Kolberg-Liedtke, C., ... Stickeler, E. (2022). Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer. Geburtshilfe und Frauenheilkunde, 82(9), 912-921. https://doi.org/10.1055/a-1912-7105

@article{a73183cc659c455d9a81389dbaff959c,

title = "Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer",

abstract = "This review summarizes recent developments in the prevention and treatment of patients with early-stage breast cancer. The individual disease risk for different molecular subtypes was investigated in a large epidemiological study. With regard to treatment, new data are available from long-term follow-up of the Aphinity study, as well as new data on neoadjuvant therapy with atezolizumab in HER2-positive patients. Biomarkers, such as residual cancer burden, were investigated in the context of pembrolizumab therapy. A Genomic Grade Index study in elderly patients is one of a group of studies investigating the use of modern multigene tests to identify patients with an excellent prognosis in whom chemotherapy may be avoided. These and other aspects of the latest developments in the diagnosis and treatment of breast cancer are described in this review.",

author = "Fehm, \{Tanja N\} and Manfred Welslau and Volkmar M{\"u}ller and Diana L{\"u}ftner and Florian Sch{\"u}tz and Fasching, \{Peter A\} and Wolfgang Janni and Christoph Thomssen and Isabell Witzel and Erik Belleville and Michael Untch and Marc Thill and Hans Tesch and Nina Ditsch and Lux, \{Michael P\} and Bahriye Aktas and Maggie Banys-Paluchowski and Andreas Schneeweiss and Cornelia Kolberg-Liedtke and Hartkopf, \{Andreas D\} and Achim W{\"o}ckel and Hans-Christian Kolberg and Nadia Harbeck and Elmar Stickeler",

note = "The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).",

year = "2022",

month = sep,

doi = "10.1055/a-1912-7105",

language = "English",

volume = "82",

pages = "912--921",

journal = "Geburtshilfe und Frauenheilkunde",

issn = "0016-5751",

publisher = "Georg Thieme Verlag",

number = "9",

}

Fehm, TN, Welslau, M, Müller, V, Lüftner, D, Schütz, F, Fasching, PA, Janni, W, Thomssen, C, Witzel, I, Belleville, E, Untch, M, Thill, M, Tesch, H, Ditsch, N, Lux, MP, Aktas, B, Banys-Paluchowski, M, Schneeweiss, A, Kolberg-Liedtke, C, Hartkopf, AD, Wöckel, A, Kolberg, H-C, Harbeck, N & Stickeler, E 2022, 'Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer', Geburtshilfe und Frauenheilkunde, vol. 82, no. 9, pp. 912-921. https://doi.org/10.1055/a-1912-7105

TY - JOUR

T1 - Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer

AU - Fehm, Tanja N

AU - Welslau, Manfred

AU - Müller, Volkmar

AU - Lüftner, Diana

AU - Schütz, Florian

AU - Fasching, Peter A

AU - Janni, Wolfgang

AU - Thomssen, Christoph

AU - Witzel, Isabell

AU - Belleville, Erik

AU - Untch, Michael

AU - Thill, Marc

AU - Tesch, Hans

AU - Ditsch, Nina

AU - Lux, Michael P

AU - Aktas, Bahriye

AU - Banys-Paluchowski, Maggie

AU - Schneeweiss, Andreas

AU - Kolberg-Liedtke, Cornelia

AU - Hartkopf, Andreas D

AU - Wöckel, Achim

AU - Kolberg, Hans-Christian

AU - Harbeck, Nadia

AU - Stickeler, Elmar

N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).

PY - 2022/9

Y1 - 2022/9

N2 - This review summarizes recent developments in the prevention and treatment of patients with early-stage breast cancer. The individual disease risk for different molecular subtypes was investigated in a large epidemiological study. With regard to treatment, new data are available from long-term follow-up of the Aphinity study, as well as new data on neoadjuvant therapy with atezolizumab in HER2-positive patients. Biomarkers, such as residual cancer burden, were investigated in the context of pembrolizumab therapy. A Genomic Grade Index study in elderly patients is one of a group of studies investigating the use of modern multigene tests to identify patients with an excellent prognosis in whom chemotherapy may be avoided. These and other aspects of the latest developments in the diagnosis and treatment of breast cancer are described in this review.

AB - This review summarizes recent developments in the prevention and treatment of patients with early-stage breast cancer. The individual disease risk for different molecular subtypes was investigated in a large epidemiological study. With regard to treatment, new data are available from long-term follow-up of the Aphinity study, as well as new data on neoadjuvant therapy with atezolizumab in HER2-positive patients. Biomarkers, such as residual cancer burden, were investigated in the context of pembrolizumab therapy. A Genomic Grade Index study in elderly patients is one of a group of studies investigating the use of modern multigene tests to identify patients with an excellent prognosis in whom chemotherapy may be avoided. These and other aspects of the latest developments in the diagnosis and treatment of breast cancer are described in this review.

U2 - 10.1055/a-1912-7105

DO - 10.1055/a-1912-7105

M3 - Journal articles

C2 - 36110894

SN - 0016-5751

VL - 82

SP - 912

EP - 921

JO - Geburtshilfe und Frauenheilkunde

JF - Geburtshilfe und Frauenheilkunde

IS - 9

ER -

Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer

Abstract

UN SDGs

Research Areas and Centers

DFG Research Classification Scheme

Access to Document

Fingerprint

Cite this